Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles

Diabetes, Obesity and Metabolism

Volumn 18, Issue 6, 2016, Pages 558-570

  Krentz, A J ^a   Fujioka, K ^b   Hompesch, M ^a  

^a Profil Institute for Clinical Research   (United States)

^b SCRIPPS CLINIC   (United States)

Author keywords

antiobesity drug; cannabinoids; glucagon like peptide 1 analogue; obesity therapy; type 2 diabetes

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; AMFEPRAMONE; AMINOREX; BENFLUOREX; BENZPHETAMINE; DEXFENFLURAMINE; FENFLURAMINE; LIRAGLUTIDE; LORCASERIN; MAZINDOL; METHAMPHETAMINE; PHENDIMETRAZINE; PHENMETRAZINE; PHENTERMINE; PHENTERMINE PLUS TOPIRAMATE; PHENYLPROPANOLAMINE; PLACEBO; RIMONABANT; SIBUTRAMINE; TARANABANT; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; ANTIOBESITY AGENT;

ABDOMINAL PAIN; ACUTE PANCREATITIS; ANXIETY; BLOATING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHOLECYSTITIS; CHOLELITHIASIS; CHRONIC PANCREATITIS; CONGENITAL MALFORMATION; CONSTIPATION; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELEVATED BLOOD PRESSURE; EUROPEAN MEDICINES AGENCY; FATIGUE; FECES INCONTINENCE; FLATULENCE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART INFARCTION; HEART RATE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INSOMNIA; IRRITABILITY; LIVER FAILURE; LIVER INJURY; NAUSEA; NAUSEA AND VOMITING; NON FATAL MYOCARDIAL INFARCTION; NON FATAL STROKE; OBESITY; PULMONARY HYPERTENSION; REVIEW; SEIZURE; SIDE EFFECT; SPOTTING; SUICIDAL IDEATION; TACHYCARDIA; THYROID TUMOR; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VALVULAR HEART DISEASE; VOMITING; XEROSTOMIA; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; UNITED STATES; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; DRUG APPROVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; OBESITY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WEIGHT LOSS;

EID: 85010930965     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12657     Document Type: Review

References (147)

1. Ng M, Fleming T, Robinson M et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384: 766–781.
2. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA 2010; 303: 235–241.
3. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, and health risk. Arch Intern Med 2000; 160: 898–904.
4. Kopelman P. Health risks associated with overweight and obesity. Obes Rev 2007; 8(Suppl. 1): 13–17.
5. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007; 298: 2028–2037.
6. Michalakis K, Mintziori G, Kaprara A, Tarlatzis BC, Goulis DG. The complex interaction between obesity, metabolic syndrome and reproductive axis: a narrative review. Metabolism 2013; 62: 457–478.
7. Garg SK, Maurer H, Reed K, Selagamsetty R. Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes Obes Metab 2014; 16: 97–110.
8. Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol 2014; 20: 8351–8363.
9. Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes Obes Metab 2010; 12: 186–194.
10. Wing RR, Lang W, Wadden TA et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011; 34: 1481–1486.
11. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311: 74–86.
12. Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care 2015; 38: 1161–1172.
13. Wharton S, Serodio KJ. Next generation of weight management medications: implications for diabetes and CVD risk. Curr Cardiol Rep 2015; 17: 35.
14. Caterson ID, Finer N, Coutinho W et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab 2012; 14: 523–530.
15. Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol 2015; 31: 142–152.
16. Charakida M, Khan T, Johnson W et al. Lifelong patterns of BMI and cardiovascular phenotype in individuals aged 60-64 years in the 1946 British birth cohort study: an epidemiological study. Lancet Diabetes Endocrinol 2014; 2: 648–654.
17. Hall KD, Sacks G, Chandramohan D et al. Quantification of the effect of energy imbalance on bodyweight. Lancet 2011; 378: 826–837.
18. Wadden TA, Webb VL, Moran CH, Bailer BA. Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation 2012; 125: 1157–1170.
19. Donnelly JE, Blair SN, Jakicic JM et al. American College of Sports Medicine position stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Med Sci Sports Exerc 2009; 41: 459–471.
20. Look ARG, Wing RR, Bolin P et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369: 145–154.
21. Carvajal R, Wadden TA, Tsai AG, Peck K, Moran CH. Managing obesity in primary care practice: a narrative review. Ann N Y Acad Sci 2013; 1281: 191–206.
22. Blomain ES, Dirhan DA, Valentino MA, Kim GW, Waldman SA. Mechanisms of weight regain following weight Loss. ISRN Obes 2013; 2013: 210524.
23. Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg 2014; 149: 275–287.
24. Brethauer SA, Kothari S, Sudan R et al. Systematic review on reoperative bariatric surgery: American Society for Metabolic and Bariatric Surgery Revision Task Force. Surg Obes Relat Dis 2014; 10: 952–972.
25. Hainer V. [Drug treatment of obesity–current situation and perspectives]. Cas Lek Cesk 2010; 149: 513–519 [Article in Czech].
26. Kang JG, Park CY. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J 2012; 36: 13–25.
27. Derosa G, Maffioli P. Anti-obesity drugs: a review about their effects and their safety. Expert Opin Drug Saf 2012; 11: 459–471.
28. Rodgers RJ, Tschop MH, Wilding JP. Anti-obesity drugs: past, present and future. Dis Model Mech 2012; 5: 621–626.
29. Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Ther Adv Chronic Dis 2014; 5: 135–148.
30. Cheung B, Cheung TT, Samranayake NS. Safety of antiobesity drugs. Ther Adv Drug Saf 2013; 4: 171–181.
31. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–720.
32. Krentz AJ. Management of type 2 diabetes in the obese patient: current concerns and emerging therapies. Curr Med Res Opin 2008; 24: 401–417.
33. Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2014; 2: 911–922.
34. Kim GW, Lin JE, Blomain ES, Waldman SA. New advances in models and strategies for developing anti-obesity drugs. Expert Opin Drug Discov 2013; 8: 655–671.
35. Clapham JC, Arch JR. Thermogenic and metabolic antiobesity drugs: rationale and opportunities. Diabetes Obes Metab 2007; 9: 259–275.
36. Pearce EN. Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes 2012; 19: 408–413.
37. Colman E. Dinitrophenol and obesity: an early twentieth-century regulatory dilemma. Regul Toxicol Pharmacol 2007; 48: 115–117.
38. Haslam D. Weight management in obesitypast and present. Int J Clin Pract 2016; 70: 206–217.
39. Cohen PA, Goday A, Swann JP. The return of rainbow diet pills. Am J Public Health 2012; 102: 1676–1686.
40. Elangbam CS. Review paper: current strategies in the development of anti-obesity drugs and their safety concerns. Vet Pathol 2009; 46: 10–24.
41. Krentz AJ, Morrow L, Hompesch M. Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm. Drugs 2012; 72: 1709–1711.
42. Elangbam CS. Drug-induced valvulopathy: an update. Toxicol Pathol 2010; 38: 837–848.
43. Food and Drug Administration. Guidance for industry developing products for weight management, 2007. Available from URL: http://www.fda.gov/downloads/Drugs/Guidances/ucm071612.pdf. Accessed 1 October 2015.
44. Colman E. Food and drug administration's obesity drug guidance document: a short history. Circulation 2012; 125: 2156–2164.
45. Sonnenberg G, Matfin G, Reinhardt RR. Drug treatments for obesity: where are we heading and how do we get there? Br J Diabetes Vasc Dis 2007; 7: 111–118.
46. European Medicines Agency. Guideline on clinical evaluation of medicinal products used in weight control, EMA/CHMP/311805/2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170278.pdf. Accessed 1 October 2015.
47. Hiatt WR, Thomas A, Goldfine AB. What cost weight loss? Circulation 2012; 125: 1171–1177.
48. Jindal A, Whaley-Connell A, Brietzke S, Sowers JR. Therapy of obese patients with cardiovascular disease. Curr Opin Pharmacol 2013; 13: 200–204.
49. Cunningham JW, Wiviott SD. Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit. Clin Cardiol 2014; 37: 693–699.
50. Ferguson C, David S, Divine L et al. The George Washington University, School of Public Health and Health Services, Department of Health Policy. Obesity drug outcome measures. A consensus report of considerations regarding pharmacologic intervention. Washington DC, 2012. Accessed 1 October 2015.
51. Kahan S, Ferguson C, David S, Divine L. Obesity drug outcome measures: results of a multi-stakeholder critical dialogue. Curr Obes Rep 2013; 2: 128–133.
52. Greenway FL, Whitehouse MJ, Guttadauria M et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring) 2009; 17: 30–39.
53. Day JW, Ottaway N, Patterson JT et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009; 5: 749–757.
54. Toplak H, Ziegler O, Keller U et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005; 7: 699–708.
55. Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes Obes Metab 2006; 8: 206–213.
56. Hess R, Cross LB. The safety and efficacy of lorcaserin in the management of obesity. Postgrad Med 2013; 125: 62–72.
57. Henry RR, Chilton R, Garvey WT. New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications 2013; 27: 508–518.
58. Bray GA, Ryan DH. Update on obesity pharmacotherapy. Ann N Y Acad Sci 2014; 1311: 1–13.
59. Fujioka K. Current and emerging medications for overweight or obesity in people with comorbidities. Diabetes Obes Metab 2015; 17: 1021–1032.
60. Smith SR, O'Neil PM, Astrup A et al. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring) 2014; 22: 2137–2146.
61. Krentz AJ, Hompesch M. Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift? Drugs 2013; 73: 1649–1651.
62. Redon J. Hypertension in obesity. Nutr Metab Cardiovasc Dis 2001; 11: 344–353.
63. Wofford MR, Hall JE. Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 2004; 10: 3621–3637.
64. Milic S, Lulic D, Stimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol 2014; 20: 9330–9337.
65. Charakida M, Finer N. Drug treatment of obesity in cardiovascular disease. Am J Cardiovasc Drugs 2012; 12: 93–104.
66. Iughetti L, China M, Berri R, Predieri B. Pharmacological treatment of obesity in children and adolescents: present and future. J Obes 2011; 2011: 928165.
67. Xiong GL, Gadde KM. Combination phentermine/topiramate for obesity treatment in primary care: a review. Postgrad Med 2014; 126: 110–116.
68. Padwal RS, Pajewski NM, Allison DB, Sharma AM. Using the edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity. CMAJ 2011; 183: E1059–E1066.
69. Colman E, Golden J, Roberts M, Egan A, Weaver J, Rosebraugh C. The FDA's assessment of two drugs for chronic weight management. N Engl J Med 2012; 367: 1577–1579.
70. VIVUS. QSYMIA (phentermine and topiramate extended-release): U.S. Food and Drug Administration, 2013. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022580s004lbl.pdf. Accessed 1 November 2015.
71. Margulis AV, Mitchell AA, Gilboa SM et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012; 207: e1–e7.
72. Bray GA. Drug insight: appetite suppressants. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 89–95.
73. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs 2005; 65: 1391–1418.
74. Michelakis ED, Weir EK. Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am J Med Sci 2001; 321: 292–299.
75. Fishman AP. Aminorex to fen/phen: an epidemic foretold. Circulation 1999; 99: 156–161.
76. Weintraub M, Sundaresan PR, Madan M et al. Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo. Clin Pharmacol Ther 1992; 51: 586–594.
77. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998; 339: 719–724.
78. Kernan WN, Viscoli CM, Brass LM et al. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000; 343: 1826–1832.
79. Mersfelder TL. Phenylpropanolamine and stroke: the study, the FDA ruling, the implications. Cleve Clin J Med 2001; 68: 208–219, 13–19, 23.
80. Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 2001; 161: 1814–1824.
81. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002; 26: 262–273.
82. Di Marzo V, Ligresti A, Cristino L. The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int J Obes (Lond) 2009; 33(Suppl. 2): S18–S24.
83. Vettor R, Pagano C. The role of the endocannabinoid system in lipogenesis and fatty acid metabolism. Best Pract Res Clin Endocrinol Metab 2009; 23: 51–63.
84. Scheen AJ, Paquot N. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders. Best Pract Res Clin Endocrinol Metab 2009; 23: 103–116.
85. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 2006; 30(Suppl. 1): S13–S18.
86. Cluny NL, Chambers AP, Vemuri VK et al. The neutral cannabinoid CB(1) receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav 2011; 97: 537–543.
87. Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity. J Clin Pharm Ther 2011; 36: 10–18.
88. Ioannides-Demos LL, Piccenna L, McNeil JJ. Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011; 2011: 179674.
89. Samat A, Tomlinson B, Taheri S, Thomas GN. Rimonabant for the treatment of obesity. Recent Pat Cardiovasc Drug Discov 2008; 3: 187–193.
90. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706–1713.
91. Aronne LJ, Tonstad S, Moreno M et al. A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. Int J Obes (Lond) 2010; 34: 919–935.
92. Addy C, Wright H, Van Laere K et al. The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 2008; 7: 68–78.
93. Proietto J, Rissanen A, Harp JB et al. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study. Int J Obes (Lond) 2010; 34: 1243–1254.
94. Chorvat RJ, Berbaum J, Seriacki K, McElroy JF. JD-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities. Bioorg Med Chem Lett 2012; 22: 6173–6180.
95. Lean ME. Sibutramine–a review of clinical efficacy. Int J Obes Relat Metab Disord 1997; 21(Suppl. 1): S30–S36; discussion 7–9.
96. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 2000; 1: 127–139.
97. Poston WS, Foreyt JP. Sibutramine and the management of obesity. Expert Opin Pharmacother 2004; 5: 633–642.
98. Bosello O, Carruba MO, Ferrannini E, Rotella CM. Sibutramine lost and found. Eat Weight Disord 2002; 7: 161–167.
99. Torp-Pedersen C, Caterson I, Coutinho W et al. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. Eur Heart J 2007; 28: 2915–2923.
100. Scheen AJ. Cardiovascular risk-benefit profile of sibutramine. Am J Cardiovasc Drugs 2010; 10: 321–334.
101. James WP, Caterson ID, Coutinho W et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905–917.
102. Astrup A. Drug management of obesity–efficacy versus safety. N Engl J Med 2010; 363: 288–290.
103. Downey M, Still C, Sharma AM. Is there a path for approval of an antiobesity drug: what did the Sibutramine Cardiovascular Outcomes Trial find? Curr Opin Endocrinol Diabetes Obes 2011; 18: 321–327.
104. Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs 1999; 58: 743–760.
105. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31: 53–65.
106. Zhou YH, Ma XQ, Wu C et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLoS One 2012; 7: e39062.
107. Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ. Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 2006; 29: 277–302.
108. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004; 3: CD004094.
109. Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. Orlistat and the risk of acute liver injury: self controlled case series study in UK Clinical Practice Research Datalink. BMJ 2013; 346: f1936.
110. Wilding J. Orlistat: should we worry about liver inflammation? BMJ 2013; 346: f2777.
111. Zelber-Sagi S, Kessler A, Brazowsky E et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4: 639–644.
112. Menard J. Benfluorex: analysis of a drug-related public health crisis. Diabetes Metab 2011; 37: 169–175.
113. Boutet K, Frachon I, Jobic Y et al. Fenfluramine-like cardiovascular side-effects of benfluorex. Eur Respir J 2009; 33: 684–688.
114. Savale L, Chaumais MC, Cottin V et al. Pulmonary hypertension associated with benfluorex exposure. Eur Respir J 2012; 40: 1164–1172.
115. Mullard A. Mediator scandal rocks French medical community. Lancet 2011; 377: 890–892.
116. Andrejak M, Tribouilloy C. Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis 2013; 106: 333–339.
117. Szymanski C, Andrejak M, Peltier M, Marechaux S, Tribouilloy C. Adverse effects of benfluorex on heart valves and pulmonary circulation. Pharmacoepidemiol Drug Saf 2014; 23: 679–686.
118. Derumeaux G, Ernande L, Serusclat A et al. Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus. PLoS One 2012; 7: e38273.
119. Harvey N, Judge A. Benfluorex and mortality: a fresh perspective. Epidem Res Int 2013. Available from URL: http://dxdoiorg/101155/2013/490309. Accessed dd mm yyyy.
120. Astrup A, Rossner S, Finer N, Van Gaal L. Obesity in Europe – does anybody care? Expert Opin Pharmacother 2013; 14: 971–973.
121. European Medicines Agency. Refusal of the Marketing Authorisation for Qsiva (phentermine/topiramate), London: European Medicines Agency, 2012. Availablefrom URL: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/002350/WC500134085.pdf Accessed 1 November 2015.
122. Rothman RB, Baumann MH. Serotonergic drugs and valvular heart disease. Expert Opin Drug Saf 2009; 8: 317–329.
123. Smith SR, Fujioka K, Gupta AK et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab 2013; 15: 863–866.
124. Greenway FL, Fujioka K, Plodkowski RA et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595–605.
125. Kim GW, Lin JE, Valentino MA, Colon-Gonzalez F, Waldman SA. Regulation of appetite to treat obesity. Exp Rev Clin Pharmacol 2011; 4: 243–259.
126. Hollander P, Gupta AK, Plodkowski R et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36: 4022–4029.
127. Takeda. Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study): U.S. National Institutes of Health (NIH); 2014. Available from URL: http://clinicaltrials.gov/ct2/show/NCT01601704?term=Contrave+in+the+Light+Study&rank=1. Accessed dd mm yyyy.
128. Astrup A, Rossner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606–1616.
129. Astrup A, Carraro R, Finer N et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012; 36: 843–854.
130. Lean ME, Carraro R, Finer N et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond) 2014; 38: 689–697.
131. Wadden TA, Hollander P, Klein S et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) 2013; 37: 1443–1451.
132. Egan AG, Blind E, Dunder K et al. Pancreatic safety of incretin-based drugs–FDA and EMA assessment. N Engl J Med 2014; 370: 794–797.
133. Liraglutide 3.0 mg for Weight Management Briefing Document. Available from URL: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm413318.pdf Accessed 1 November 2015.
134. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013; 3:e001986.
135. Marso SP, Poulter NR, Nissen SE et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013; 166: 823–830.e5.
136. Pi-Sunyer X, Astrup A, Fujioka K et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015; 373: 11–22.
137. Krentz AJ, Fujioka K, Hompesch M. Anti-obesity pharmacotherapy: the intercontinental regulatory divide. Drugs 2015; 75: 931–933.
138. Wolfe SM. When EMA and FDA decisions conflict: differences in patients or in regulation? BMJ 2013; 347: f5140.
139. Kim GW, Lin JE, Blomain ES, Waldman SA. Antiobesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther 2014; 95: 53–66.
140. Jones BJ, Bloom SR. The new era of drug therapy for obesity: the evidence and the expectations. Drugs 2015; 75: 935–945.
141. Diaz MB, Herzig S, Vegiopoulos A. Thermogenic adipocytes: from cells to physiology and medicine. Metabolism 2014; 63: 1238–1249.
142. Arch JR. Beta(3)-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol 2002; 440: 99–107.
143. Cypess AM, Weiner LS, Roberts-Toler C et al. Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist. Cell Metab 2015; 21: 33–38.
144. Hsiao WC, Shia KS, Wang YT et al. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis. Diabetes Obes Metab 2015; 17: 495–504.
145. Dawson JA, Hall KD, Thomas DM, Hardin JW, Allison DB, Heymsfield SB. Novel mathematical models for investigating topics in obesity. Adv Nutr 2014; 5: 561–562.
146. Thomas DM, Ivanescu AE, Martin CK et al. Predicting successful long-term weight loss from short-term weight-loss outcomes: new insights from a dynamic energy balance model (the POUNDS Lost study). Am J Clin Nutr 2015; 101: 449–454.
147. Fujioka K. Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring) 2015; 23(Suppl. 1): S7–S11.